Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
7°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Zai Lab Limited
< Previous
1
2
3
Next >
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
June 06, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
NVCR
ZLAB
Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting
June 01, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Participation in June Investor Conferences
May 25, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA
May 18, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
May 09, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
April 27, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
April 20, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
April 11, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
March 20, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
KRTX
ZLAB
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
March 01, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Participation in March Investor Conferences
February 28, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
February 22, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
February 22, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
February 09, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Participation in February Investor Conferences
January 31, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
January 30, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
January 18, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
January 09, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
January 05, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
NVCR
ZLAB
Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
January 03, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Participation in January Investor Conferences
December 20, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary
December 15, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
December 05, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
November 09, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
November 08, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
November 08, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Participation in November Investor Conferences
October 31, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
October 18, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Launches its first Trust Report
October 14, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.